Results 191 to 200 of about 13,840,459 (217)

Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration

Immunotherapy, 2013
Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in patients over the age of 50 in the western world. Intravitreally administered anti-VEGF drugs have been developed to halt neovascular growth in AMD. Randomized trials have demonstrated the excellent safety profile and significant benefit of anti-VEGF therapy ...
David, Xu, Peter K, Kaiser
openaire   +2 more sources

Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration: A Mixed-Methods Systematic Review

Ophthalmology, 2021
James S Talks, Luciano Paladini, Anat Loewenstein   +2 more
exaly  

Archway Randomized Phase 3 Trial of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration

Ophthalmology, 2022
Shienal Patel, Daniel Miller, Shrirang Ranade   +2 more
exaly  

Diagnostic Accuracy of Monitoring Tests of Fellow Eyes in Patients With Unilateral Neovascular Age-Related Macular Degeneration: Early Detection of Neovascular Age-Related Macular Degeneration Study

Ophthalmology, 2021
Graham Scotland, Andrew J Lotery, Sobha Sivaprasad   +2 more
exaly  

Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group

Ophthalmology, 2020
Ramin Tadayoni, Frank G Holz, David S Boyer   +2 more
exaly  

Macular atrophy development in neovascular age-related macular degeneration

European Journal of Ophthalmology, 2020
Dan Călugăru, Mihai Călugăru
openaire   +2 more sources

Efficacy, Durability, and Safety of Intravitreal Faricimab Up to Every 16 Weeks for Neovascular Age-Related Macular Degeneration (TENAYA and LUCERNE): Two Randomised, Double-Masked, Phase 3, Non-Inferiority Trials

Lancet, The, 2022
Geeta Menon, Frank G Holz, András Seres
exaly  

Neovascular age-related macular degeneration

2010
David E Lederer, Scott W Cousins, Karl G Csaky   +2 more
openaire   +2 more sources

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

Ophthalmology, 2020
Frank G Holz, Ursula Schmidt-Erfurth, Yuichiro Ogura   +2 more
exaly  

Gene Therapy With Recombinant Adeno-Associated Vectors for Neovascular Age-Related Macular Degeneration: 1 Year Follow-Up of a Phase 1 Randomised Clinical Trial

Lancet, The, 2015
Ian J Constable, Martyn A. French, Mariapia A Degli-Esposti   +2 more
exaly